



Why do we need to assess older patients with cancer?
Epidemiological studies show us that the ageing population which is well known to clinicians and healthcare planners will continue to increase in number.  With increasing age the development of cancer becomes more likely and many older individuals will be diagnosed with a malignancy in later life or may survive from a younger age with such a diagnosis.  As individuals age there is little doubt that co-morbidity becomes a major issue in the presence or absence of cancer.  Although clinicians may view older people as being a minor part of their day to day workload, there are few specialities with the obvious exceptions of obstetrics and paediatrics who do not deal with older people on a daily basis.  Within the last ten to twenty years there has been an increasing awareness of geriatric oncology as a specialty in its own right and many have attempted to measure co-morbidity to improve the management of patients with cancer.  The giants of geriatric medicine as described by Bernard Isaacs (incontinence, instability and falls, impaired hearing and vision and intellectual decline) are all more prevalent with increasing age.  Other conditions particularly related to environmental exposure are also frequently present.  Co-morbidities are highly relevant to the prognosis of cancer patients.  This is in part due to the effect on prognosis of the additional co-morbidities, but also their influence on the treatment of such patients.

When observing elderly women with breast cancer, it becomes abundantly clear that biological and chronological age are not identical.  Despite similar genetic make up and environmental factors, one 80 year old may be physically and mentally robust and the other may exhibit the frailty syndrome.

There are three occasions when the clinical assessment of an older person with breast cancer is important.  Firstly, prior to the decision to undertake therapy a full assessment of the patient’s suitability for surgery and/or adjuvant therapy must be determined.  Without attention to comorbidity, patient selection may not be ideal, therapy may not be evidence based and untreated comorbidity will not be identified and actively managed.  Secondly, during treatment it is vital that response to therapy is monitored and this must include the continued assessment of existing conditions and an active search for the development of new conditions which may or may not be related to therapy.  Thirdly and perhaps more important for service planning, is the assessment of disease free survival, as well as overall survival.  To many older people, the argument of quantity versus quality may result in patient derived decisions being made which are different from clinicians.

What assessment methodologies have been used in the past?
Extermann in her 1999 review, identified four commonly used measures of comorbidity and reported, not only a systematic review of these methodologies, but also an expert opinion on each of the indices.  She studied the Charlson Comorbidity Index, the Cumulative Illness Rating Scale (CIRS), the Index of Coexistent Disease (ICED) and the Kaplan-Feinstein Index.1 

The Charlson Comorbidity Index
The Charlson Comorbidity Index was designed in 1987 and was initially used in general internal medicine patients to analyse mortality at one year, as a result of different comorbidities.  Whilst it was not developed for use in patients with malignant disease, it was validated in a cohort of breast cancer patients using ten year mortality as the end point.  It has been used to predict mortality, outcomes of post operative complications, length of hospital stay and discharge to a nursing home.  Its validation in the older cancer patient has resulted in it being widely used.  Whilst the Charlson has good inter-rater and test-retest reliability, it does have some problems.  It ignores certain comorbidities, including hematopoietic disorders and moderate renal dysfunction, both of which may be critical in patients who may have impaired renal function as a consequence of ageing, or haematological problems due to bone marrow infiltration or chemotherapy.  It must also be remembered that four of the Charlson items relate to cancer and therefore the use of this scale in patients with a primary diagnosis of breast cancer may result in skewed results.  

The Cumulative Illness Rating Scale (CIRS)
This assessment scale was first designed in 1968 and assesses comorbidities according to the organ system affected and the severity of the affect.  The items use a 0-4 scale, i.e. none, mild, moderate, severe, extremely severe/life threatening.  Although the CIRS score does correlate with hospitalisation rates, hospital readmission, medication usage, functional disability and mortality, it has been less used in elderly patients within oncology.  It correlates well with the Charlson when studying prognosis, although unfortunately unless the observer is using the CIRS regularly, the assessment of disease severity often includes errors.  

The Index of Coexistent Disease (ICED)
This scale was developed in 1987 and addresses both physical and functional ability.  It assesses the presence and severity of fourteen different categories of conditions.  It has been validated in patients with breast cancer and correlates with both the intensity of treatment, as well as the use of axillary node dissection in breast cancer.  Unfortunately the ICED like the CIRS requires a considerable amount of medical knowledge to ensure that the severity of diseases is accurately determined and therefore a relatively senior clinician is required to complete; thus limiting its usefulness in everyday practice.

The Kaplan-Feinstein Index
This Index which was developed in 1974 has a narrower rating of severity (0-3) of a number of conditions that are considered to impair a patient’s long term survival.  It has been used in patients with breast cancer, where it has been found to correlate with mortality. 2 

Surgical Assessment Scales
There are a number of surgical assessment scales that may be more appropriate to the pre operative assessment of elderly women with breast cancer.  They include both APACHE and POSSUM.

The Acute Physiology and Chronic Health Evaluation (APACHE) Index
The APACHE was first published in 1981 and then replaced in 1985 by APACHE II.  It includes twelve physiological parameters, usually measured during the first 24 hours after admission to an intensive care unit.  Headley and colleagues found that patients with breast cancer admitted to the intensive care unit, had their mortality accurately predicted using the APACHE II score.3

Physiological and Operative Severity Score in Enumeration of Mortality and Morbidity (POSSUM)
This scale developed by Copeland and colleagues in the North West in 1991 was initially used as a scoring system for hospital audit.  It predicts morbidity and post operative mortality in general surgery.  Its usefulness has been assessed as part of the initial validation of PACE (Preoperative Assessment of Cancer in the Elderly), but has had no other formal evaluation in older people with breast cancer.4

There are few papers that have compared APACHE II, POSSUM and ASA (American Society of Anesthesiologists) scoring systems.  Much of the comparison has been undertaken in patients with head and neck tumours which clearly influence maintenance of airway, respiratory complications and the issues of local tumour dissection.5  Little evidence exists in breast cancer patients.


Adult Co-morbidity Evaluation-27 (ACE-27)
The ACE-27 was initially derived from the Kaplan-Feinstein Index (KFI).6  Its usefulness in older patients with tumours related to alcohol and cigarette smoking, is well documented but data in breast cancer patients are lacking.7

Comprehensive Geriatric Assessment
The Comprehensive Geriatric Assessment (CGA) evaluates a number of aspects of normal ageing.  This enables patients to be thoroughly assessed in a holistic fashion, to ensure that their pre-treatment comorbidities are treated and the overall outcome of any specific cancer treatment is optimised.  It is essential that the Comprehensive Geriatric Assessment includes measures of functional status, comorbidity, nutritional status, drug therapy, socioeconomic issues and the presence of geriatric syndromes.  The CGA will ensure that all patients at the time of treatment selection receive appropriate therapy and even the frailest benefit from palliative treatment.8

There is little doubt that many of the frailest individuals with breast cancer will benefit from active intervention.  It is known that outside oncology, the CGA is very effective when planning the management of frail, older individuals with complex medical needs.  The CGA is superior to usual care in the management of older patients with common conditions, such as hip fracture and congestive cardiac failure.  A number of randomized controlled trials have tested the effectiveness of CGA in the care of older patients in a variety of settings.9

Whilst it might be considered that co-morbidities are different in patients with and without cancer, when one compares the 10 most prevalent comorbid conditions in age match groups; arthritis, hypertension, digestive cardiac and vascular diseases, constitute the top 5 in both cancer and non-cancer elderly patients.10
CGA has been used frequently in a variety of cancer and non-cancer studies.  Even in the early 1990’s a systematic review identified 28 trials that had employed comprehensive assessments.  Unfortunately the majority of these trials were studying a variety of geriatric medicine services such as day hospitals, hospital at home, as well as looking at chronic care management models.11   

The CGA can be used in both relatively fit and the most frail.  In a review by Wieland and Hirth the use of CGA in the most frail and oldest old providing cost effective care within the US.  This also provides evidence for the use of CGA in elderly patients from outside Europe thus providing more evidence for a standardised form of assessment.12

It is vital that frailty is identified and quantified.  A frailty index CGA (FI-CGA) has been used to identify different levels of frailty i.e. mild, moderate and severe and not surprisingly has found that greater frailty is associated with worse functional and mental status.  In a Canadian study, the FI-CGA allowed identification of those most at risk, for both decompensation of clinical status and mortality.  They found that higher levels of frailty were associated with an increase in risk of an adverse outcome of death or institutionalisation and the risk was highest for those with the most severe frailty.  Although they found limited benefit in the intervention group (multidisciplinary input), the population was so frail with a number of irreversible geriatric syndromes, that this finding may not be entirely surprising.13

How does CGA compare with other assessment scales?
In an Italian study of cancer patients aged up to 94 years, CGA was assessed by its comparison with performance status, using both ADL and IADL.  This prospective study allowed early identification of the frailest patients and therefore ensured provision of individualised cancer management.  They found up to a third of individuals required help with transportation and 13% of required some form of assistance, to enable them to take their prescribed medication.  Although many of these issues were identified by the ADL and the IADL, the authors were keen to stress that these individual scoring systems were merely of the CGA.14

There has been speculation about the role of the CGA in various sub groups of elderly patients with cancer.  The CGA may add information to some groups, but not others.  In a study of over 360 elderly cancer patients, the CGA was compared with performance status and comorbidity and assessed by logistic regression.15 The majority of the patients were independent in activities of daily living and this is not a consistent finding in all cancer patients.  Repetto and colleagues found a strong association between CGA and performance status particularly in those elderly patients who had a good performance status at baseline.  They in keeping with others, found arthritis to be the most common comorbid condition, but somewhat surprisingly found only a prevalence of 5.2% for urinary incontinence and 0.3% of their patients had dementia.  This does therefore cause concern as to whether their selected patients were truly representative of those seen in everyday geriatric medicine practice.

The use of the CGA in older patients with cancer, not only detects the geriatric syndromes/problems, but adds prognostic value to each of the variables that are measured if there is a therapeutic impact of the CGA.
 
Extermann suggests that the performance status of patients undergoing therapy for cancer has deteriorated since the 1990’s.16   She suggests that in many series almost half of the cancer patients have two or more comorbidities, with the result that health problems in the older cancer patients are high.  

Survival
A systematic review undertaken by Kuo and colleagues in 2004 identified nine studies providing survival data on patients in whom a CGA had been undertaken.17  Their study which incorporated all papers published on Medline from 1966 to March 2003, included papers where there was a randomized trial of outpatient CGA versus usual care.  The majority of the studies were in primary care, with only three in a hospital consultation setting.  They found that outpatient CGA had no demonstrable benefit for the survival of frail, older patients when compared to usual care.  Whilst statistically convincing, there are notable deficiencies in this systematic review.  It did expand the earlier meta-analysis of CGA, performed by Stuck and colleagues in 1993, but included only studies from the US.  It did not include either in-patient or home usage of CGA and was poorly powered.  Such findings should not discourage clinicians from using the CGA in the in-patient setting and in frail patients with cancer.  
Who should have a CGA performed?
There remains some doubt as to which patients are ideal candidates for the CGA.18  There is little doubt that it is not necessary in younger, fit cancer patients, but some suggest that even fit older cancer patients should undergo the CGA.  What is quite clear is its positive role in the very frail when making decisions about treatment and prognosis.  However, there are a number of older individuals with cancer in whom the CGA may potentially pick up early stage disability and geriatric syndromes, which are treatable.  It is essential that the CGA is evaluated in prospective clinical trials to ensure that the oncology profession continue to use it.  In patients with breast cancer, those receiving a CGA have a better prognosis, than in non-CGA patients although numbers studied are small.

Despite oncologists and geriatricians working together, there is often some doubt as to whether a patient can tolerate aggressive life prolonging treatment, following a diagnosis of cancer.  Treatment has a variety of effects on a patient and a number of issues are present that may have been previously undetected.  The CGA may therefore help in the management of older individuals by detecting frailty, ensuring that there is treatment of previously unsuspected conditions and ensuring that all social barriers to treatment are removed to ensure that no ageist attitudes occur.19

What is the evidence in breast cancer?
In a pilot study, 15 patients with early breast cancer, with a mean age of 79 years were assessed every 3 months by a multi-disciplinary team, for a total of 6 months.  They found that from this small sample, comorbidities as measured by the CIRS-G ranged between 3 and 9 (median 5).  Two thirds of patients were at pharmacological risk, a third at psychosocial risk and just over half at nutritional risk.  Whilst initially each patient had on average six problems, a further three problems developed during follow-up.20  This study highlighted that even when there were a limited number of comorbidities, patients were at risk from a variety of other problems and each required on average 17 recommendations or actions.  Of the 184 interventions undertaken, 48 were multi-disciplinary and 50 were pharmacy led.  More importantly, the patients did appear to benefit as determined by both the researcher’s assessment, but also patient self-reported questionnaires.  The authors concluded that a full Comprehensive Geriatric Assessment being performed every 3 months was too cumbersome and indeed one of the issues during follow-up was patients being outside the geographical area at times of re-review.  They suggested that telephone follow-up by a nurse practitioner, followed by targeted interventions by particular specialists, may be a way forward in the future but studies need to be undertaken.

In the US study of older patients with early breast cancer, a CGA performed every 3 months with monthly telephone follow-up, detected on average 6 un-addressed or under-addressed problems at the initial examination and a further three new problems over the following 6 months.  With this in mind tailoring the therapy, according to “identified issues” appears to be both pragmatic and well validated.  Areas such as cognition and social support interact affect decision making and drug compliance and interact with issues such as functional dependence.  Extermann has highlighted that a multi-disciplinary team may use the CGA in a constructive fashion.  The team includes a nurse, a nurse practitioner who then administers the core geriatric assessment, a dietician, a social worker and a pharmacist.  The team meets weekly, thereby enabling the patient to access support in the areas required.  The full CGA is only undertaken if the primary nurse identifies patients at risk from a short screening protocol, which may suggest that her case mix is different from others where all individuals required the CGA.16

What is the evidence in breast cancer?
Wedding and Höffken in 2003 advocated the use of CGA in breast cancer patients.21  They found that in a  2003 PUBMED search, combining the search term “breast cancer” and “geriatric assessment”, resulted in 27 items.  Unfortunately since then there has been little substantial change in the situation, and whilst a further 16 papers are now identified, the only papers with original data are confined to small prospective studies.20,22  Although other authors have used the CGA in patients with breast cancer to identify the number with no comorbidity (26.4%).23

Some of the later validation of CGA in breast cancer patients has been through its inclusion in PACE (Pre-operative Assessment of Cancer in the Elderly).  Whilst PACE includes CGA, it also has a measure of fatigue and performance status.  It is not however within PACE being used to assess the selection of patients prior to surgery, but simply to document the presence of comorbidity.24

Does the CGA correlate with laboratory measures?
Whilst CGA has been compared to a number of measures of physical, emotional and social functioning, there is little data about the correlation between serum pro-inflammatory cytokines, including IL-6 and CGA. IL-6 plays a major role in acute inflammatory response and high levels of IL-6 and TNF-have been found in both patients and animals with cancer.  There has been particular interest in IL-6 due to its association with the development of cancer cachexia which is common in older cancer patients.  In a study of 84 elderly patients with advanced cancer, a number of clinical characteristics, as well as measures of serum levels of proinflammatory cytokines were undertaken.  Mantovani and colleagues found that IL-6 and CRP were significantly higher in elderly (65-96 years) cancer patients than adult cancer patients (<65 years).  They found a significant association between serum levels of IL-6 and CGA variables in the elderly cancer patients, IL-6 also correlated well with CGA variables, with a statistically significant Spearman’s Rank correlation coefficient, between measures of functional status using CATZ ADL, IADL and nutritional status.  Whilst the authors suggested that IL-6 may be a reliable marker as disease outcome, it is interesting to speculate whether the now clear association between CGA variables and IL-6 merely confirm that CGA is a good indicator of outcome and IL-6 may be useful in the prospective follow up of cancer patients.25

Application of comprehensive geriatric assessment in clinical practice
There is little doubt that many authors advocate the use of geriatric assessment in the elderly cancer patient, in an effort to avoid impairment of activities and performance, recognise the need for supporting independence and delay or avoid the need for care and the resulting dependence.26  It is also important that the patient is enabled to remain at home in his or her familiar environment and the importance of a number of social issues, including income, availability of transportation and home support, will undoubtedly influence the tolerance of different cancer treatments.27  Whilst CGA has been advocated by a number of authors, taskforces and as a result of courses on the management of older people with cancer, some people find it long and cumbersome.28-31  In these cases the abbreviated comprehensive geriatric assessment (a-CGA) may be more appropriate.  The a-CGA was developed by selection of various instruments that make up the CGA.  Fifteen items were chosen and the a-CGA was validated in over 500 patients with cancer, of whom 43% had a primary diagnosis of breast cancer.32  Unfortunately however, there was no assessment of the time taken for the a-CGA to be administered, as it was part of a larger battery of tests.  The authors however, have suggested that it may take as little as 5 minutes, when compared with the 30 minutes to administer the CGA.  The full use of the a-CGA in identifying patients who require more intensive assessment, has been recommended.33

Whilst there is little doubt by individual clinicians, taskforce groups, or organisations of oncologists and geriatricians, that there is a role for assessment of older people with cancer, there is still a poverty of published data.  The taskforce on CGA from the International Society of Geriatric Oncology (SIOG) were quite clear in their 2005 recommendations that there was evidence to support the use of CGA in elderly cancer patients.30  They found that although CGA was well used within geriatric medicine, its relevance in oncology was difficult to determine, as most of the data was from patients who may incidentally have cancer, rather than from a primary group of elderly individuals with cancer.  There is very little doubt that the CGA when used in the oncology clinic does identify unrecognised geriatric problems.  However, the data does not determine whether these problems would have been identified by the involvement of a geriatrician or a clinician skilled in geriatric medicine.  Thus it may be that the CGA simply identifies deficiencies in training and further supports the increased collaboration of geriatricians with oncologists.  Of particular concern is the under recognition of cognitive impairment and depression and whilst the former should have been identified in the community prior to the presentation of the individual with cancer, the latter may be simply related to the new diagnosis, rather than to a pre-existing condition.

If the CGA improves survival in only those individuals with advanced stage disease and not early stage cancer, it must be considered as to whether the CGA has been used to identify co-existing conditions that were more likely to result in death, than as a result of the tumour itself.  There is little data that tells us whether the CGA alone has influenced the treatment that oncologists and surgeons offer to their patients with breast cancer.  Although PACE may turn out to be an alternative to CGA, the need for a short screening test which the a-CGA provides, may target the use of PACE in the future.  In future research it must be quite clear as to the primary outcomes of any study, using a-CGA or CGA prior to the treatment of an older person with cancer.  This will unfortunately be a difficult study to undertake.  The ethics of identifying co-existing comorbidity and not treating it is clearly difficult.  It must therefore fall to individual clinicians when designing research studies, to ensure that primary and secondary outcomes are clear, that patient quality of life has as high a priority as quantity i.e. survival and that individual patients help determine outcome measures that are important to them.

Whilst geriatricians and oncologists continue to work together and there is a large body of evidence that has developed from the International Society of Geriatric Oncology, there is still a gap between research data and application of clinical practice.  Undoubtedly the CGA has much to offer in the early assessment and ongoing monitoring of elderly patients with breast cancer, although data is still at times anecdotal or the result of retrospective analysis.
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